US Patent 7855058 Human cyclin-dependent kinase (hPNQALRE)
Patent 7855058 was granted and assigned to Novartis on December, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+276 characters)
Article
Patent abstract
A human gene encoding a novel cyclin-dependent kinase termed hPNQALRE and its expression products can be used to provide reagents and methods for detecting neoplasia. Compositions and methods for treating proliferative disorders and neoplasia are also provided.
Edits on 18 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Christoph Reinhard0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07855058 Human cyclin-dependent kinase (hPNQALRE) US Patent 7855058 Human cyclin-dependent kinase (hPNQALRE)
Infobox
Patent Number
078550580
Patent Number
78550580
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078550580
Date of Patent
December 21, 2010
0Patent Application Number
117597260
Date Filed
June 7, 2007
0Official Website
Patent Primary Examiner
Edits on 4 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07855058 Human cyclin-dependent kinase (hPNQALRE)
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07855058
Date of patent
December 21, 2010
Patent application number
11759726
Date Filed
June 7, 2007
Patent primary examiner
Find more entities like US Patent 7855058 Human cyclin-dependent kinase (hPNQALRE)
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
